Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 25;13(19):5711.
doi: 10.3390/jcm13195711.

Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations

Oliver Illini  1   2 , Hannah Fabikan  2 , Eva Fischer  3 , Anna Sophie Lang-Stöberl  2 , Dagmar Krenbek  4 , Christa Jarius  4 , Shokoufa Azarnia-Medan  5 , Stefan Gasser  6 , Maximilian Johannes Hochmair  1   2 , Christoph Weinlinger  2 , Arschang Valipour  1   2 , Stefan Watzka  7   8
Affiliations

Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations

Oliver Illini et al. J Clin Med. .

Abstract

Background: Adenosquamous carcinoma of the lung (ASC) is a rare non-small-cell lung cancer (NSCLC) subtype combining components of squamous cell carcinoma (SCC) and adenocarcinoma (AC). Data on ASC, particularly in Caucasian populations, are limited. Methods: We reviewed clinicopathological and radiological characteristics of ASC patients diagnosed between 1996 and 2023. Patients were classified into AC-predominant ASC (AC-ASC) and SCC-predominant ASC (SCC-ASC) groups for analysis. Results: Among the 66 patients included, the median overall survival was 41.7 (95% CI, 25.0-54.4), while it was 48.1 (95% CI, 27.3-88.0) in patients treated with curative surgery (n = 44) and 15.3 (95% CI, 6.5-42.6) months for palliative patients (n = 22). The five-year survival rates were 39% and 26%, respectively. Recurrence occurred in 43% of stage I patients and was associated with worse survival (HR 3.303 (95% CI, 1.10-9.89) p = 0.033). AC-ASCs (n = 17) more frequently showed air-bronchogram (p = 0.002) and pleural effusions (p = 0.054) compared to SCC-ASCs (n = 26). SCC-ASCs exhibited more vascular invasion (p = 0.006) and PD-L1 values between 1 and 49% (TPS) (p = 0.032). The subtype did not influence survival. EGFR and ALK alterations were found in 17% and 2% of patients, respectively. Conclusions: Despite early-stage disease, ASC patients had a high recurrence rate, associated with worse survival. Clinicopathologic differences between AC-ASCs and SCC-ASCs did not influence survival.

Keywords: EGFR; PD-L1; adenosquamous carcinoma; lung cancer; pathological subtypes; prognostic factors.

PubMed Disclaimer

Conflict of interest statement

Illini O. received speaker fees and/or honoraria for advisory boards from Boehringer Ingelheim, Eli Lilly, Janssen-Cilag, Menarini, Merck Sharp and Dohme, Pfizer, and Roche. Research grants from Amgen and AstraZeneca were received outside of the submitted study. Fabikan H. declares that there are no conflicts of interest. Fischer E. declares that there are no conflicts of interest. Lang-Stöberl A.S. declares that there are no conflicts of interest. Krenbek D. received speaker fees and/or honoraria for advisory boards from Eli Lilly, Merck Sharp and Dohme, Pfizer, and Roche. Jarius C. declares that there are no conflicts of interest. Azarnia-Medan S. declares that there are no conflicts of interest. Gasser S. declares that there are no conflicts of interest. Hochmair M. reports personal fees for lectures, consultancy, and participation in advisory boards from Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Lilly Oncology, Roche, MSD, Pfizer, and Takeda Oncology. Weinlinger C. declares that there are no conflicts of interest. Valipour A. reports personal fees for lectures, consultancy, and participation in advisory boards from Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, and Menarini. Watzka S. reports speaker fees from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp and Dohme.

Figures

Figure 1
Figure 1
Flowchart of the study.
Figure 2
Figure 2
Overall survival (OS) analysis. (a). OS curves for all patients with curative surgical or palliative treatment (p = 0.077). (b). OS curves for patients with curative surgical treatment who had a recurrence and who did not have a recurrence (p = 0.009); (c). OS curves for patients with curative surgical treatment whose tumor contours were either spiculated or smooth (p = 0.037); (d). OS curves for patients with curative surgical treatment with and without additional chemo- and/or immunotherapy (p = 0.325).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Li C., Lu H. Adenosquamous Carcinoma of the Lung. OncoTargets Ther. 2018;11:4829–4835. doi: 10.2147/OTT.S164574. - DOI - PMC - PubMed
    1. Travis W.D., Brambilla E., Nicholson A.G., Yatabe Y., Austin J.H.M., Beasley M.B., Chirieac L.R., Dacic S., Duhig E., Flieder D.B., et al. The 2015 World Health Organization Classification of Lung Tumors. J. Thorac. Oncol. 2015;10:1243–1260. doi: 10.1097/JTO.0000000000000630. - DOI - PubMed
    1. Handa Y., Ikeda T., Hanaki H., Miyata Y., Mukaida H., Okada M. Clinicopathologic Study of Stage I Adenosquamous Carcinoma of the Lung. Jpn. J. Clin. Oncol. 2023;53:1201–1207. doi: 10.1093/jjco/hyad122. - DOI - PubMed
    1. Mordant P., Grand B., Cazes A., Foucault C., Dujon A., Le Pimpec Barthes F., Riquet M. Adenosquamous Carcinoma of the Lung: Surgical Management, Pathologic Characteristics, and Prognostic Implications. Ann. Thorac. Surg. 2013;95:1189–1195. doi: 10.1016/j.athoracsur.2012.12.037. - DOI - PubMed
    1. Powrózek T., Krawczyk P., Ramlau R., Sura S., Wojas-Krawczyk K., Kucharczyk T., Walczyna B., Szumiło J., Szyszka-Barth K., Milecki P., et al. EGFR Gene Mutations in Patients with Adenosquamous Lung Carcinoma: EGFR Mutations in ADSQ Cell Carcinoma. Asia Pac. J. Clin. Oncol. 2014;10:340–345. doi: 10.1111/ajco.12177. - DOI - PubMed

LinkOut - more resources